Curated News
By: NewsRamp Editorial Staff
March 17, 2026
Aclarion Showcases Pain-Detection Tech at Investor Conference
TLDR
- Aclarion's participation in the ROTH Conference presents an investment opportunity to gain early insight into Nociscan's expansion and the company's strong, debt-free financial position.
- Aclarion's Nociscan platform uses MR spectroscopy data, proprietary signal processing, biomarkers, and AI algorithms to help physicians identify painful discs in chronic low back pain patients.
- Aclarion's Nociscan technology helps physicians better diagnose chronic low back pain, potentially leading to more effective treatments and improved patient outcomes worldwide.
- Aclarion is showcasing its AI-powered Nociscan platform at the ROTH Conference, using biomarkers from MR scans to pinpoint sources of back pain.
Impact - Why it Matters
Chronic low back pain is a leading cause of disability worldwide, often leading to invasive diagnostic procedures and treatments with mixed results due to difficulty pinpointing the exact source of pain. Aclarion's Nociscan technology represents a significant advancement in noninvasive diagnostics. By providing objective, biomarker-based data to help distinguish painful from nonpainful spinal discs, it could reduce diagnostic uncertainty, help avoid unnecessary surgeries, and enable more targeted, effective treatment plans. For patients, this means a potential path to more accurate diagnoses and better outcomes. For the healthcare system, it could lead to more efficient use of resources and reduced costs associated with chronic pain management. The company's participation in a major investor conference highlights its growth phase and the potential for this technology to scale, impacting how back pain is diagnosed and treated globally.
Summary
Aclarion, Inc., a commercial-stage healthcare technology company trading on Nasdaq under the symbols ACON and ACONW, has announced its participation in the upcoming 38th Annual ROTH Conference in Dana Point, California, from March 22-24, 2026. The company, which specializes in leveraging biomarkers and proprietary augmented intelligence algorithms to address chronic low back pain, will be represented by CEO Brent Ness. He will engage in one-on-one meetings with institutional investors and analysts to discuss the company's strategic progress and key catalysts for the year ahead, emphasizing Aclarion's strong financial position with no debt and a focused expansion strategy.
The core of these discussions will center on Nociscan, Aclarion's flagship proprietary MR spectroscopy platform. This innovative SaaS solution is designed to noninvasively help physicians identify painful discs in patients suffering from chronic low back pain. By analyzing magnetic resonance spectroscopy data through cloud-based, proprietary signal processing, Nociscan extracts and quantifies chemical biomarkers associated with disc pain. This technology provides critical insights that, when combined with other diagnostic tools, aims to give physicians greater clarity in optimizing treatment strategies for a condition that affects millions globally.
CEO Brent Ness expressed optimism about the company's trajectory, stating, "We look forward to engaging with the investment community at ROTH to share the progress we are making and the important catalysts ahead for Aclarion." The company is actively working to expand adoption of Nociscan in both the United Kingdom and the United States. For more information, stakeholders are directed to visit the company's website or check the Latest News section. The press release was distributed via the trusted PRISM MediaWire press release distribution service, underscoring the formal announcement's reach to the investment and healthcare communities.
Source Statement
This curated news summary relied on content disributed by PRISM Mediawire. Read the original source here, Aclarion Showcases Pain-Detection Tech at Investor Conference
